Merus (MRUS) Stock Price, News & Analysis

Company Overview

Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company’s research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.

The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development. Key programs are being evaluated in solid tumors and hematological malignancies, with a focus on innovative mechanisms of action that harness T cell redirection, immune checkpoint modulation and co-stimulatory pathways. In addition to its internal development efforts, Merus collaborates with strategic partners to advance select programs and expand its therapeutic reach.

Headquartered in Utrecht, the Netherlands, Merus maintains operations in both Europe and the United States, supporting global clinical trials and regulatory activities. The company completed its initial public offering on the Nasdaq stock market in October 2018, and its research sites extend from the Dutch biotech hub to a dedicated U.S. presence in Boston’s ecosystem.

Merus is led by a management team with extensive experience in oncology drug development and commercialization. Under the leadership of Chief Executive Officer Ton Logtenberg, the company continues to advance its bispecific antibody platform, aiming to deliver transformative treatments for patients with unmet medical needs.

Key Stats

• Today's Range: $67.13 to $68.58
• 50-Day Range: $52.33 to $68.55
• 52-Week Range: $33.19 to $69.20
• Volume: 76,253 shs
• Average Volume: 842,619 shs
• Market Capitalization: $5.17 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $88.75
• Consensus Rating: Buy

Merus Stock Analysis - MarketRank™

Merus scored higher than 57% of companies evaluated by MarketBeat, and ranked 367th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Merus has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Merus has a consensus price target of $88.75, representing about 29.7% upside from its current price of $68.42.

Amount of Analyst Coverage

Merus has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Merus are expected to decrease in the coming year, from ($3.85) to ($4.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Merus is -12.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Merus is -12.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Merus has a P/B Ratio of 7.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.99% of the float of Merus has been sold short.

Short Interest Ratio / Days to Cover

Merus has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Merus has recently decreased by 1.80%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Merus does not currently pay a dividend.

Dividend Growth

Merus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.99% of the float of Merus has been sold short.

Short Interest Ratio / Days to Cover

Merus has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Merus has recently decreased by 1.80%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.29

News Sentiment

Merus has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Merus this week, compared to 7 articles on an average week.

Search Interest

6 people have searched for MRUS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Merus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Merus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,586,340.00 in company stock.

Percentage Held by Insiders

Only 3.70% of the stock of Merus is held by insiders.

Percentage Held by Institutions

96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MRUS Stock Analysis - Frequently Asked Questions

How have MRUS shares performed this year?

Merus' stock was trading at $42.05 on January 1st, 2025. Since then, MRUS shares have increased by 62.7% and is now trading at $68.4150.

How were Merus' earnings last quarter?

Merus N.V. (NASDAQ:MRUS) issued its quarterly earnings results on Tuesday, August, 5th. The biotechnology company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($1.17) by $1.06. The biotechnology company had revenue of $8.83 million for the quarter, compared to the consensus estimate of $9.77 million. Merus had a negative net margin of 685.64% and a negative trailing twelve-month return on equity of 50.28%.

When did Merus IPO?

Merus (MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Who are Merus' major shareholders?

Merus' top institutional investors include Commodore Capital LP (4.66%), Holocene Advisors LP (2.94%), Westfield Capital Management Co. LP (2.70%) and Franklin Resources Inc. (2.43%). Insiders that own company stock include Sven Ante Lundberg, Harry Shuman and Peter B Silverman.
View institutional ownership trends.

How do I buy shares of Merus?

Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Merus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Merus investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE), Jabil (JBL) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 9/11/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRUS
• CIK: 1651311
• Web: www.merus.nl
• Phone: (130) 253-8800
• Fax: N/A
• Employees: 37
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Merus: $88.75
• High Price Target: $110.00
• Low Price Target: $70.00
• Potential Upside/Downside: +32.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.08
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$215.33 million
• Net Margins: -685.64%
• Pretax Margin: -670.59%
• Return on Equity: -50.28%
• Return on Assets: -42.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.39
• Quick Ratio: 8.39

Sales & Book Value

• Annual Sales: $36.13 million
• Price / Sales: 140.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.46 per share
• Price / Book: 7.10

Miscellaneous

• Outstanding Shares: 75,630,000
• Free Float: 72,836,000
• Market Cap: $5.08 billion
• Optionable: Optionable
• Beta: 1.19